TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00253071

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prophylactic combined medical and psychological treatment
Description: Medical treatment is naturalistic and evidence based according to international recommendations.~Psychological treatment is either group psychoeducation or group cognitive behavioural therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic combined medical and psychological treatment
Description: Medical treatment is naturalistic and evidence based according to international recommendations.~Psychological treatment is either group psychoeducation or group cognitive behavioural therapy.
Study: NCT01054209

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Warming with warming mattress
Description: Reusable pressure relieving warming mattress. Principle use is to warm patients to prevent hypothermia peri-operatively.~Inditherm Alpha systems, OTM1: 1900mm x 585mm
Study: NCT01913613

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IASD
Description: IASD device implantation
Study: NCT03175809

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PFM training
Description: The PFM training will be delivered with an electromyographic biofeedback (bEMG). In order to perform the muscular training, the Biotrainer software was used, the training protocol will follow a rationale of evolutionary complexity throughout each session. The training protocols will focus on both muscle relaxation and contraction training and coordination.The parameters for the biofeedback will be tailored to the participant's presentation and will be determined and adjusted between each session as needed by the treating therapist. The treatment parameters will be determined by the treating therapist based on the participant's assessment that will be conducted at each treatment session. The Maximum voluntary contraction will be assessed at the beginning of each training day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PFM training
Description: The PFM training will be delivered with an electromyographic biofeedback (bEMG). In order to perform the muscular training, the Biotrainer software was used, the training protocol will follow a rationale of evolutionary complexity throughout each session. The training protocols will focus on both muscle relaxation and contraction training and coordination.The parameters for the biofeedback will be tailored to the participant's presentation and will be determined and adjusted between each session as needed by the treating therapist. The treatment parameters will be determined by the treating therapist based on the participant's assessment that will be conducted at each treatment session. The Maximum voluntary contraction will be assessed at the beginning of each training day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: The dry needling technique will be applied to the abdominal muscles (external oblique, rectus abdominis), lumbar spine (lumbar multifidus and erector spinae) and hip muscles (piriformis, gluteus medius, psoas major and adductors). Both active of latent myofascial trigger points will be treated with sterile stainless steel needles (0.25x0.4 mm or 0.2x0,7mm, DongBang, Korea). After diagnosis of the area of muscle pain, the tight band of the muscle will be palpated and the needle will be introduced subcutaneously. The second insertion will be toward the muscle point until a local twitch response (LTR) is elicited. Then the needle will be removed and the area will be compressed for 30 seconds.
Study: NCT00886626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Exenatide, subcutaneous injection, 10 mcg, twice per day
Study: NCT02701660

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electronic medication dispenser (medido)
Description: Automated dispense of medication through an electronic dispenser
Study: NCT04136717

Intervention type: OTHER
Group type: OTHER
Intervention: Washout period
Description: During this period the patients will breath spontaneously oxygen titrated using the FreeO2 device with a SpO2 target set at 90%. The period duration is 30 minutes.

Intervention type: DEVICE
Group type: OTHER
Intervention: NIV - FreeO2
Description: During this period the patients will receive NIV using FreeO2 device for oxygen titration with a SpO2 target set at 90%. Initially, the inspiratory pressure will be set to obtain a tidal volume between 6 to 8 mL/Kg of predictive body weight and positive end-expiratory end pressure (PEEP) at 5 centimeters of water (cmH2O).~After NIV initiation, the parameters can be adjusted to improve patient comfort. The period duration is 30 minutes.

Intervention type: DEVICE
Group type: OTHER
Intervention: Nasal High flow Oxygen therapy - FreeO2
Description: During this period the patients will receive NHFOT using the FreeO2 device for oxygen titration with a SpO2 target set at 90%. The high flow device will be set at 30 lpm.The period duration is 30 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: CPAP - Oxygen constant flow
Description: During this period, the patients will have their own CPAP with oxygen adjusted by hospital staff according to hospital protocol. The period duration is 15 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: CPAP - FreeO2
Description: During this period, the patients will have their own CPAP with oxygen adjusted using the FreeO2 device. SpO2 target will be set at 90% The period duration is 60 minutes.
Study: NCT02843321

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-cell infusion, influenza vaccination
Description: Donor derived infection-specific T-cells (with activity against CMV,adenovirus, EBV, VZV, Influenza, BKV and Aspergillus) and vaccination (with Fluvax)
Study: NCT01290549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Participants will receive escalating intravenous dose of polatuzumab vedotin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Participants will receive escalating intravenous dose of polatuzumab vedotin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered by an IV infusion at 375 mg/m\^2 body surface area dose q3w.
Study: NCT03408639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CinnaPoietin®
Description: The starting dose of Erythropoietin is 60 (50-100) IU/kg body weight/week for naïve patients. Administration dose for patients who are treated with erythropoietin is similar dose of previously administered amount (IV or SC without any change). After then, dose adjustment will be done based on patients' response.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eprex®
Description: The starting dose of Erythropoietin is 60 (50-100) IU/kg body weight/week for naïve patients. Administration dose for patients who are treated with erythropoietin is similar dose of previously administered amount (IV or SC without any change). After then, dose adjustment will be done based on patients' response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nephrovit
Description: Nephrovit tablet is daily administered to all the patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nephrovit
Description: Nephrovit tablet is daily administered to all the patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B12 Injection
Description: Vitamin B12 is monthly injected to all the patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12 Injection
Description: Vitamin B12 is monthly injected to all the patients.
Study: NCT00548639

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Statin Choice Decision Aid
Description: Paper based instrument with pictures indicating level of risk.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Pamphlet
Description: ADA Diabetes Sheet
Study: NCT02269098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes medication management
Description: As above plus- Follow-up intervention visits were at 24-72 hrs, 2 and 4 weeks. During each, further DSME was provided, BG logs reviewed, and diabetes medications adjusted as needed by the CDE. Meter and insulin injections skills were reinforced as needed. Outpatient navigation included securing a primary care appointment no later than 4 weeks after study completion. Final contact was via telephone at 90 days. The MMS© (Morisky Medication Adherence Survey) was taken at 2 and 4 weeks and during the final telephone visit. Interim return visits to the ED or admissions to the hospital were queried at each visit. A follow up HbA1C was obtained at week 4 using the POC A1CNow+ ®, and a venous HbA1C was drawn if the POC result was above 13% .
Study: NCT02963779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2775240
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2775240
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apremilast
Description: Administered orally
Study: NCT01689051

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: human glucagon-like peptide 1 (7-36)amide

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: human glucagon-like peptide 1 (7-36)amide

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: human glucagon-like peptide 1 (9-36)amide

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: human glucagon-like peptide 1 (9-36)amide
Study: NCT01287806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ulinastatin
Description: Resolved 4 vials of drugs in 100ml physiological saline solution,intravenously infused for 1-2h,tid,for continuous 10days

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: blank group
Description: standard treatment
Study: NCT00247715

Intervention type: DRUG
Group type: OTHER
Intervention: algeldrate/magnesium oxide

Intervention type: DRUG
Group type: OTHER
Intervention: algeldrate/magnesium oxide

Intervention type: DRUG
Group type: OTHER
Intervention: ranitidine

Intervention type: DRUG
Group type: OTHER
Intervention: ranitidine

Intervention type: DRUG
Group type: OTHER
Intervention: pantoprazole

Intervention type: DRUG
Group type: OTHER
Intervention: pantoprazole
Study: NCT02243150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G1T28-1 (CDK 4/6 Inhibitor)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G1T28-1 (CDK 4/6 Inhibitor)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G1T28-1 (CDK 4/6 Inhibitor)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G1T28-1 (CDK 4/6 Inhibitor)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G1T28-1 (CDK 4/6 Inhibitor)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03426774

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Gentle Jogger
Description: Passive Simulated Jogging device (Gentle Jogger)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gentle Jogger
Description: Passive Simulated Jogging device (Gentle Jogger)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gentle Jogger
Description: Passive Simulated Jogging device (Gentle Jogger)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Gentle Jogger
Description: Passive Simulated Jogging device (Gentle Jogger)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Gentle Jumper
Description: Passive Simulated Jumping Device ( Gentle Jumper)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gentle Jumper
Description: Passive Simulated Jumping Device ( Gentle Jumper)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gentle Jumper
Description: Passive Simulated Jumping Device ( Gentle Jumper)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Gentle Jumper
Description: Passive Simulated Jumping Device ( Gentle Jumper)
Study: NCT02246205

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreaticoduodenectomy
Description: Pancreaticoduodenectomy is the classical operative technique to resect cephalic pancreatic cancer. In a first phase of the surgery, the resection may be performed. In the second phase, the digestive tract must be restored. We planify two different reconstruction techniques.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreaticoduodenectomy
Description: Pancreaticoduodenectomy is the classical operative technique to resect cephalic pancreatic cancer. In a first phase of the surgery, the resection may be performed. In the second phase, the digestive tract must be restored. We planify two different reconstruction techniques.
Study: NCT01258751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212377
Description: Single dose of up to 70 mg PF-05212377, delivered as .25 mg, 5 mg and/or 15 mg on study day 1
Study: NCT01995656

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Capsule
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Capsule
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3108743 - Capsule
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3108743 - Capsule
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Solution
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3108743 - Solution
Description: Administered orally
Study: NCT02267343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03217058

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic-based screening and behavioral interventions
Description: As part of routine HIV primary care visits, patients will complete self-administered computerized substance use, anxiety and depression screening measures. Results will be integrated into the electronic health record. A behavioral health specialist on the clinic staff will contact patients who screen positive for high-risk substance use, anxiety or depression, and offer behavioral interventions including motivational interviewing and cognitive behavioral therapy.
Study: NCT04221373

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ekso™ powered exoskeleton
Description: Powered exoskeletal-assisted walking (EAW) for early training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Participants will receive standard of care of acute inpatient rehabilitation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Participants will receive standard of care of acute inpatient rehabilitation.
Study: NCT04904952

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine tablet 600mg
Description: N-acetylcysteine tablet 600mg/day and doubling weekly to reach a maximum dose of 2400mg/day (at week-3) for remaining 7 weeks along with SSRIs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet 600mg
Description: Placebo tablet 600mg/day and doubling weekly to reach a maximum dose of 2400mg/day (at week-3) for remaining 7 weeks along with SSRIs
Study: NCT01946295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: 100mg x 2 p.o.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00467051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given IV or subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT03740152

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Light Therapy
Description: Device: LiteCure® The PhotoBioModulation-1000 (TPBM-1000)
Study: NCT04420975

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Definitive Surgical Resection
Description: Undergo definitive surgical resection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nanoplexed Poly I:C BO-112
Description: Given intratumorally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT04425876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Fluzoparib combined with mFOLFIRINOX followed by maintenance Fluzoparib monotherapy
Study: NCT03130634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silymarin
Description: During six cycles of FOLFIRI chemotherapy, the patients will take silymarin (150mg) three times daily from day 1 to day 7 during one cycle of treatment.
Study: NCT03096249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Syntocinon nasal spray: single dose of 24IU (3 puffs of 4IU per nostril)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo spray: single dose (3 puffs per nostril).
Study: NCT03626935

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D-printed customized guide plate
Description: 3D-printed customized guide plate will be used in the ankle arthrodesis to help reduce operation time and reduce intra-operative radiation.
Study: NCT03479957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REMOTE-CR
Description: The patients randomized to remotely monitored exercise can either work out with self-selected activities e.g. Nordic-walking, cycling, skiing or participate in supervised exercise session via video link. Remotely monitored exercise training sessions will be offered monday-friday 13.00-16.00.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: The patients randomized to be controls will receive individualized information and instructions regarding current exercise recommendations but will not be monitored or coached during their exercise sessions (usual care)
Study: NCT04066127

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-ischemic heart preservation (NIHP)
Description: The device is a miniaturized and fully automated heart-lung machine, housed in a portable device (weight 32 kg), that enables transportation between hospitals. The reservoir is filled with 2.5 liters of the perfusion solution plus approximately 500 mL compatible washed and leucocyte-filtered red blood cells from the hospital blood bank. The NIHP system software is adjusted to maintain a mean blood pressure of 20-25 mmHg in the aortic root, giving a coronary flow between 150 mL/min and 250 mL/min.

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard ischemic cold static storage (SCS)
Description: The device is a cool box that enables transportation between hospitals. The heart is stored on ice slush in the box at a temperature of approximately 4-8 °C.
Study: NCT01172327

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise
Description: This intervention is a self-directed, multicomponent, exercise intervention. Participants exercise on their own and follow a progressive stepped program that occurs in the following order: cardiorespiratory exercises, flexibility exercises, strength (upper and lower body) exercises, and balance exercises. Participants also complete a daily log of their exercises and return the logs every week for 12 weeks. The active intervention phase is 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition
Description: This arm is a self-directed nutrition intervention. Participants follow a progressive stepped program that occurs in the following order: fruits, vegetables, grains, meat and beans. Participants also complete a daily log of their dietary intake and return the logs every week for 12 weeks. The active intervention lasts for 12 weeks.
Study: NCT02778269

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 12-lead ECG T-shirt
Description: The 12-lead ECG T-shirt system consists of three parts: the recording device, amplifier boards and the T-shirt.The T-shirt has 10 textile ECG electrode patches. The patches should be in contact with the patient's skin to record the electrical activity of the heart. The electrodes are made of electrically conductive textile. They are sewn into the inside of the T-shirt and are padded with foam. The cables to the device can be attached to snap fasteners on the outer side of the T-shirt on the ECG electrode patches.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G4-System
Description: Continuous Glucose Monitoring
Study: NCT01959217

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PM Component Text Reminders
Description: The number of PM components (strategic encoding, monitoring, and cue salience) that will comprise the tailored text reminders will be determined by Phase 1.
Study: NCT02966366

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear implant
Study: NCT03294811

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: The telemonitoring interference in the telemonitoring arm consists of a smartphone application that helps the patient to take their medication in time and to take their blood pressure and weight on a daily basis in order to improve the medication uptitration and medication compliance.
Study: NCT04520633

Intervention type: OTHER
Intervention: biologic initiation
Description: introduction or modification of biotherapy at M0
Study: NCT02353273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WH-1 ointment
Description: Each subject will be applied the one dose of WH-1 ointment on Day 1, and twice a day of WH-1 application from Day 2 to Day 13, then one dose for Day 14.
Study: NCT01481480

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Latissimus dorsi tendon transfer
Description: Latissimus dorsi tendon transfer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic repair
Description: Arthroscopic repair
Study: NCT02821572

Intervention type: BIOLOGICAL
Intervention: blood sample

Intervention type: BIOLOGICAL
Intervention: blood sample

Intervention type: PROCEDURE
Intervention: spleen sample

Intervention type: PROCEDURE
Intervention: spleen sample
Study: NCT03826056

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Current standard discharge educational intervention
Description: The patients will receive the current hospital standard discharge educational material which explains the diagnosis, new medications, follow up and any activity/diet restrictions. A member of the study team will explain this material to the patient and answer any questions.
Study: NCT04478773

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI with or without contrast